Cisplatin Superior to Cetuximab for HPV+ Oropharyngeal Cancer

MONDAY, Dec. 17, 2018 -- For treatment of human papillomavirus (HPV)-positive low-risk oropharyngeal cancer, cetuximab shows no benefit compared with the standard cisplatin regimen in terms of reduced toxicity and results in worse tumor control,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news